Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer
Leboulleux, S., Lee, E.K., Bastholt, L., Tahara, M., Wirth, L.J., Sherman, S.I., Robinson, B.G., Teng, A., Joshi, P., Misir, S., Dutcus, C.E., Tuttle, R.M., Schlumberger, M.J.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Lee, C.-H., Motzer, R.J., Glen, H., Michaelson, M.D., Larkin, J., Minoshima, Y., Kanekiyo, M., Dairiki, R., Sachdev, P., Dutcus, C.E., Funahashi, Y., Voss, M.H.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
Gianoukakis, A. G., Dutcus, C. E., Batty, N., Guo, M., Baig, M.
Published in Opukholi golovy i shei (08.11.2018)
Published in Opukholi golovy i shei (08.11.2018)
Get full text
Journal Article
Влияние прерывания терапии ленватинибом на общую эффективность лечения у пациентов с радиойодрезистентным дифференцированным раком щитовидной железы в исследовании III фазы
Tahara, M., Brose, M. S., Wirth, L. J., Suzuki, T., Miyagishi, H., Fujino, K., Dutcus, C. E., Gianoukakis, A.
Published in Opukholi golovy i shei (03.04.2019)
Published in Opukholi golovy i shei (03.04.2019)
Get full text
Journal Article
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
Taylor, M., Dutcus, C.E., Schmidt, E., Bagulho, T., Li, D., Shumaker, R., Rasco, D.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
1862PDImpact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
Tahara, M, Kiyota, N, Hoff, A O, Badiu, C, Owonikoko, T K, Dutcus, C E, Suzuki, T, Ren, M, Misir, S, Wirth, L J
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
Velcheti, V., Hida, T., Reckamp, K.L., Yang, J.C., Nokihara, H., Sachdev, P., Feit, K., Kubota, T., Nakada, T., Dutcus, C.E., Ren, M., Tamura, T.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
76PCorrelative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Lee, C-H, Motzer, R J, Glen, H, Michaelson, M D, Larkin, J, Minoshima, Y, Kanekiyo, M, Dairiki, R, Sachdev, P, Dutcus, C E, Funahashi, Y, Voss, M H
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1819OTumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer
Leboulleux, S, Lee, E K, Bastholt, L, Tahara, M, Wirth, L J, Sherman, S I, Robinson, B G, Teng, A, Joshi, P, Misir, S, Dutcus, C E, Tuttle, R M, Schlumberger, M J
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
Makker, V, Taylor, M H, Aghajanian, C, Oaknin, A, Mier, J, Cohn, A L, Marin, M Romeo, Lorenzo, R Bratos, Brose, M S, DiSimone, C, Messing, M J, Stepan, D E, Dutcus, C E, Wu, J, Schmidt, E V, Orlowski, R J, Sachdev, P, Shumaker, R, Herraez, A Casado
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1187PDPhase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
Lee, C-H, Shah, A Y, Makker, V, Taylor, M H, Shaffer, D, Hsieh, J J, Cohn, A L, DiSimone, C, Marin, A Pinto, Rasco, D W, Ribe, S G, Richards, D A, Stepan, D E, Dutcus, C E, Wu, J, Schmidt, E V, Perini, R F, Motzer, R J
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Finn, R S, Kudo, M, Cheng, A-L, Wyrwicz, L, Ngan, R, Blanc, J F, Baron, A D, Vogel, A, Ikeda, M, Piscaglia, F, Han, K-H, Qin, S, Minoshima, Y, Kanekiyo, M, Ren, M, Dairiki, R, Tamai, T, Dutcus, C E, Funahashi, Y, Evans, T R J
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Responses in specific metastases following treatment with lenvatinib (LN): Results from the phase 3 SELECT trial
Robinson, B., Schlumberger, M., Wirth, L.J., Dutcus, C.E., Binder, T.A., Guo, M., Taylor, M., Kim, S.B., Krzyzanowska, M.K., Capdevilla, J., Sherman, S.I., Tahara, M.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Finn, R.S., Kudo, M., Cheng, A.-L., Wyrwicz, L., Ngan, R., Blanc, J.F., Baron, A.D., Vogel, A., Ikeda, M., Piscaglia, F., Han, K.-H., Qin, S., Minoshima, Y., Kanekiyo, M., Ren, M., Dairiki, R., Tamai, T., Dutcus, C.E., Funahashi, Y., Evans, T.R.J.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
The relationship between age and survival outcomes for eribulin in metastatic breast cancer
Twelves, C., Vahdat, L. T., Cortes, J., Wanders, J., Dutcus, C. E., Seegobin, S., Muss, H. B.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301
Kaufman, PA, Yelle, L, Cortes, J, Perez, EA, Awada, A, Wanders, J, Olivo, MS, He, Y, Dutcus, CE, Twelves, C
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article
Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
Kaufman, PA, Awada, A, Twelves, C, Yelle, L, Perez, EA, Wanders, J, Olivo, MS, He, Y, Dutcus, CE
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Get full text
Journal Article
Abstract P3-13-03: A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival
Awada, A, Kaufman, PA, Yelle, L, Cortes, J, Wanders, J, O'Shaughnessy, J, Olivo, MS, He, Y, Garzon, F, Dutcus, CE, Binder, TA, Twelves, C, Perez, EA
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article